Oncology in 2016: reflections on successes and shortcomings

The most notable oncology development in 2016 followed the death of United States Vice President Joe Biden’s son from a brain tumor (GBM IV): Obama announced on 12 January a program called Cancer Moonshot .
Its stated aim was to understand cancer better by gathering “real-life” information rather than research-derived data and using computer analysis, or bioinformatics . In other words, it sought to accelerate understanding of cancer’s inner workings, pursued for years, through collaboration among everyone involved in cancer… Achieving 10 years of progress in 5 years…
Cancer has overtaken cardiovascular disease as the leading cause of death in the Western world. However, the number of people successfully treated and continuing healthy lives is increasing daily. Scientists, clinicians, nongovernmental organizations and politicians should devote research to these survivors as well as efforts and funding to cancer treatment itself.
Last year, the United States Food and Drug Administration, FDA, a leading authority in new drug approvals, granted approval to new-generation immunotherapy drugs for non-small-cell lung cancer . The FDA also, after 40 years, approved a new drug for soft tissue sarcoma .
Despite positive progress in treating almost every cancer type, costs of care and treatment, quality of life and geographical differences in treatment access remain major problems.
With greater knowledge of genetics and the immune system, we have begun making substantial progress in targeted and immune therapies. However, for cancer types where these promising new-generation immunotherapies have demonstrated efficacy, why they work very well for some patients but poorly for others remains incompletely understood. They are also very expensive. This issue has repeatedly been raised in many articles . More reasonable ways for patients to obtain these medicines must be found.
The number and variety of oral chemotherapy pills increase yearly, making treatment adherence and oncology education for patients and loved ones more important and adding another dimension to them.
Pediatric cancers are among those with the greatest treatment successes. In many pediatric cancer types, average 5-year survival rates, indicating complete recovery, have reached %84. Quality of life is a growing issue for children continuing their lives after treatment. Particularly in this age group, treatment side effects may cause lifelong health problems; growing numbers of studies seek the best ways to prevent long-term problems resulting from cancer treatment.
To achieve the best treatment, cancer specialists must not only research new effective drugs but also ensure they remain aware of the almost constantly developing and changing knowledge in oncology. Therefore, education for both the public and physiciansis essential to make cancer treatment possible.
New drug development and approval processes and clinical trials are very important in cancer; nevertheless, progress toward treatment also requires considering the patient as a whole and understanding their needs. Health policymakers, oncologists and cancer scientists must collaborate not only to treat cancer clinically but also to understand the process of cancer formation (carcinogenesis) better.
Sources
A Year in Review: Reflections on Successes and Shortcomings.
cancertherapyadvisor.com
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.